About CerevanceCerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company will use a new technology.
69 articles about Cerevance
Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of Parkinson’s Disease
Cerevance today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson’s disease.
Cerevance Kicks Off 2018 with Additional $10 Million of Infusions
Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has received an additional equity investment as well as a non-dilutive cash payment in the first six weeks of 2018 totaling more than $10 million.
Cerevance Appoints David H. Margolin, MD, PhD as Senior Vice President of Clinical and Translational Medicine
Prior to joining Cerevance, Dr. Margolin served in several leadership roles at Sanofi-Genzyme over a 14-year period.
Trailblazer in Molecular Genetics and Neuroscience, Jeremy Nathans, MD, PhD, to Advise Cerevance
Cerevance announced that Jeremy Nathans, M.D., Ph.D., has joined the company as a senior-level scientific advisor.
Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller University
Cerevance today announced that it has signed an agreement with The Rockefeller University to license a novel technology for profiling specific cell populations in human brain tissue.
Harvard’s Rudolph Tanzi, Ph.D., A Leader In Alzheimer’s Disease Genetics, Joins Cerevance’s Advisory Board
Stanford Neuroscientist, Robert Malenka, M.D., Ph.D., To Advise Cerevance
Dementia Discovery Fund To Invest $5 Million In Cerevance To Seek New Treatments For Dementia
Cerevance Launches With $36 Million and 25 Former Takeda Employees on Its Roster